Asked by: Paul Uppal (Conservative - Wolverhampton South West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to help women suffering from endometriosis.
Answered by Dan Poulter
Information on endometriosis is readily available to healthcare professionals and the public. Both the Royal College of Obstetricians and Gynaecologists (RCOG) and NHS Choices have published information for the public on the symptoms, diagnosis and treatment of endometriosis. Further information can be found on the RCOG website:
www.rcog.org.uk/womens-health/clinical-guidance/endometriosis-what-you-need-know
and NHS Choices website:
www.nhs.uk/conditions/Endometriosis/Pages/Introduction.aspx
To support women with endometriosis all obstetricians and gynaecologists have been trained in the diagnosis, investigation and management of the condition, which is specifically listed as a topic in the core curriculum for obstetrics and gynaecology. The European Society of Human Reproduction and Embryology has published clinical guidelines on the management of women with endometriosis to assist clinicians.
In addition, NHS England has developed a service specification for severe endometriosis under the specialised commissioning area of complex gynaecology. NHS England expects all units providing a service to women with severe endometriosis to provide care which meets the standards laid out in a specification which can be found on their website:
www.england.nhs.uk/wp-content/uploads/2014/04/e10-comp-gynae-endom-0414.pdf
Asked by: Paul Uppal (Conservative - Wolverhampton South West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what representations he has received on the applicability of the end-of-life criteria to the National Institute for Health and Care Excellence's appraisal of abiraterone acetate for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.
Answered by Norman Lamb
Since January 2013, the Department has received four questions from hon. Members, including his own, regarding the applicability of end-of-life criteria in the National Institute for Health and Care Excellence's appraisal of abiraterone (Zytiga) for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy.
In addition, we have received one letter from an hon. Member regarding this particular appraisal more generally.
Asked by: Paul Uppal (Conservative - Wolverhampton South West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what figures he holds on the life expectancy of men with metastatic castrate-resistant prostate cancer.
Answered by Jane Ellison
The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer.
Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.
Data related to men with metastatic castration-resistant prostate cancer is not collected to permit the calculation of a reliable figure for average life expectancy.
However, Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.